Anti-TNF-α and risk of infections: The experience in one center

Panminerva Medica

Volumn 56, Issue 1, 2014, Pages 31-34

  Maruotti, N ^a   D'Onofrio, F ^a   Neve, A ^a   Santoro, N ^a   Corrado, A ^a   Cantatore, F P ^b  

^a UNIVERSITY OF FOGGIA   (Italy)

^b Mario Carrozzo Rheumatology Clinic   (Italy)

Author keywords

Arthritis; Infection; Tumor necrosis factor alpha

Indexed keywords

ADALIMUMAB; CERTOLIZUMAB PEGOL; GOLIMUMAB; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN G; INFLIXIMAB; MACROGOL DERIVATIVE; METHOTREXATE; MONOCLONAL ANTIBODY; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; AGED; ANTAGONISTS AND INHIBITORS; ARTHRITIS, PSORIATIC; ARTHRITIS, RHEUMATOID; CHRONIC DISEASE; COMORBIDITY; COMPLICATION; FEMALE; HERPES ZOSTER; HUMAN; INFECTION; MALE; MEDICAL RECORD; MIDDLE AGED; RISK; RISK FACTOR; URINARY TRACT INFECTION;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ARTHRITIS, PSORIATIC; ARTHRITIS, RHEUMATOID; CHRONIC DISEASE; COMORBIDITY; FEMALE; HERPES ZOSTER; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOGLOBULIN G; INFECTION; MALE; MEDICAL RECORDS; METHOTREXATE; MIDDLE AGED; ODDS RATIO; POLYETHYLENE GLYCOLS; RECEPTORS, TUMOR NECROSIS FACTOR; RISK FACTORS; TUMOR NECROSIS FACTOR-ALPHA; URINARY TRACT INFECTIONS;

EID: 84899752463     PISSN: 00310808     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Maini RN, Feldman M. How does infliximab work in rheumatoid arthritis? Artrhitis Res 2002;4(Suppl 2):S22-8.
2. Listing J, Strangfeld A, Kary S, Rau R, von Hinueber U, Stoyanova-Scholz M et al. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum 2005;523403-12.
3. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006;295:2275-85. (Pubitemid 43736578)
4. van der Heijde D, Kivitz A, Schiff MH, Sieper J, Dijkmans BA, Braun J et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2006;54:2136-46. (Pubitemid 44051069)
5. van der Heijde D, Dijkmans B, Geusens P, Sieper J, DeWoody K, Williamson P et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 2005;52:582-91. (Pubitemid 40216323)
6. Davis JC Jr, Van Der Heijde D, Braun J, Dougados M, Cush J, Clegg DO et al. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum 2003;48:3230-36. (Pubitemid 37409337)
7. Torigo S, Ihara T, Kamiya H. IL-12, IFN-gamma, and TNF-alpha released from mononuclear cells inhibit the spread of varicellaezoster virus at an early stage of varicella. Microbiol Immunol 2000;44:1027-31 (Pubitemid 32011550)
8. Thompson AE, Rieder SW, Pope JE. Tumor necrosis factor therapy and the risk of serious infection and malignancy in patients with early rheumatoid arthritis: a meta-analysis of randomized controlled trials. Arthritis Rheum 2011;63:1479-85.
9. Baum J. Infection in rheumatoid arthritis. Arthritis Rheum 1971;14:135-7.
10. Wolfe F, Mitchell DM, Sibley JT, Fries JF, Bloch DA, Williams CA et al. The mortality of rheumatoid arthritis. Arthritis Rheum 1994;37:481-94. (Pubitemid 24115934)
11. Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE. Frequency of infection in patients with rheumatoid arthritis compared with controls: a̧ population-based study. Arthritis Rheum 2002;46:2287-93.
12. Thomas E, Symmons DP, Brewster DH, Black RJ, Macfarlane GJ. National study of cause-specific mortality in rheumatoid arthritis, juvenile chronic arthritis, and other rheumatic conditions: a 20 year followup study. J Rheumatol 2003;30:958-65. (Pubitemid 36529614)
13. Sihvonen S, Korpela M, Laippala P, Mustonen J, Pasternack A. Death rates and causes of death in patients with rheumatoid arthritis: a population-based study. Scand J Rheumatol 2004;33:221-7. (Pubitemid 39180164)
14. Boerbooms AM, Kerstens PJ, van Loenhout JW, Mulder J, van de Putte LB. Infections during low-dose methotrexate treatment in rheumatoid arthritis. Semin Arthritis Rheum 1995;24:411-21.
15. Braun J, Bollow M, Remlinger G, Eggens U, Rudwaleit M, Distler A et al. Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors. Arthritis Rheum 1998;41:58-67.
16. Cunnane G, Doran M, Bresnihan B. Infections and biological therapy in rheumatoid arthritis. Best Pract Res Clin Rheumatol 2003;17:345-63.
17. Martinez A, Pacheco-Tena C, Vazquez-Mellado J, Burgos-Vargas R. Relationship between disease activity and infection in patients with spondyloarthropathies. Ann Rheum Dis 2004;63:1338-40. (Pubitemid 39273519)
18. Glück T, Kiefmann B, Grohmann M, Falk W, Straub RH, Schölmerich J. Immune status and risk for infection in patients receiving chronic immunosuppressive therapy. J Rheumatol 2005;321473-80.
19. Zochling J, Bohl-Bühler MH, Baraliakos X, Feldtkeller E, Braun J. The high prevalence of infections and allergic symptoms in patients with ankylosing spondylitis is associated with clinical symptoms. Clin Rheumatol 2006;25:648-58. (Pubitemid 44111305)
20. Gómez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk e A multicenter active-surveillance report. Arthritis Rheum 2003;48:2122-7.
21. Askling J, Fored CM, Brandt L, Baecklund E, Bertilsson L, Feltelius N et al. Time-dependent increase in risk of hospitalization with infection among Swedish RA patients treated with TNF antagonists. Ann Rheum Dis 2007;66:1339-44.
22. Bongartz T, Warren FC, Mines D, Matteson EL, Abrams KR, Sutton AJ. Etanercept therapy in rheumatoid arthritis and the risk of malignancies: a systematic review and individual patient data meta-analysis of randomised controlled trials. Ann Rheum Dis 2009,68:1177-83.
23. Dixon WG, Watson K, Lunt M, Hyrich KL, Silman AJ, Symmons DP. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: Results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2006;54:2368-76. (Pubitemid 44204996)
24. Khanna D, McMahon M, Furst DE. Safety of tumour necrosis factor-alpha antagonists. Drug Saf 2004;27:307-24. (Pubitemid 38530461)